

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**


**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|   |   |  |
|---|---|--|
| (51) International Patent Classification <sup>4</sup> :<br><b>A61B 5/02, G06F 15/42</b>   | <b>A1</b>   | (11) International Publication Number: <b>WO 89/ 01312</b><br>(43) International Publication Date: 23 February 1989 (23.02.89) |
| (21) International Application Number: <b>PCT/US88/02833</b><br>(22) International Filing Date: <b>18 August 1988 (18.08.88)</b><br>(31) Priority Application Numbers: <b>086,972<br/>232,481</b><br>(32) Priority Dates: <b>19 August 1987 (19.08.87)<br/>17 August 1988 (17.08.88)</b><br>(33) Priority Country: <b>US</b><br>(71) Applicant: <b>BOMED MEDICAL MANUFACTURING, LTD. [US/US]; 5 Wrigley Street, Irvine, CA 92718 (US).</b><br>(72) Inventors: <b>VYSIN, Vlastimil, Pat ; 126 Ave. Cornelio, San Clemente, CA 92672 (US). SRAMEK, Bohumir ; 19211 Edgehill Drive, Irvine, CA 92715 (US).</b> | (74) Agents: <b>SIMPSON, Andrew, H. et al.; Knobbe, Martens, Olson &amp; Bear, 620 Newport Center Drive, 16th Floor, Newport Beach, CA 92660 (US).</b><br>(81) Designated States: <b>AT (European patent), BE (European patent), CH (European patent), DE (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent).</b><br>Published<br><i>With international search report.</i> |  |

## (54) Title: DIASTOLIC CLAMP FOR BIOIMPEDANCE MEASURING DEVICE



## (57) Abstract

An electrical bioimpedance measuring device is used to measure changes in the electrical resistance of a segment of the thorax of a human body caused by changes in the blood perfusion in that segment resulting from the pumping action of the heart. The electrical resistance of the thorax also changes as a result of respiration, and the respiratory-induced changes, typically much larger than the cardiac-induced changes, cause large changes in the voltages measured by the measuring equipment. In order to suppress these large voltage changes, a clamping circuit (142) is included that is synchronized with the electrical activity of the heart. The clamping circuit (142) is timed to clamp the voltages in the measuring equipment to a baseline reference voltage (144) in the time preceding the beginning of mechanical systole. The voltage clamping is released during the mechanical systole of the heart so that the changes in the voltages (i.e., the bioimpedance changes) caused by the pumping action of the heart during mechanical systole can be measured.

-1-

## DIASTOLIC CLAMP FOR BIOIMPEDANCE MEASURING DEVICE

Background of the InventionField of the Invention

5 The present invention relates to apparatus and methods  
for measuring the blood perfusion through various tissue  
segments of the human body. In particular, the invention  
relates to apparatus and methods to measure the electrical  
impedance of a segment of a human body caused by changes in  
the volume of blood in the segment.

10 Description of the Related Art

The electrical bioimpedance of a segment of a human body  
depends upon a number of factors, one of which is the  
quantity of blood and the conductivity of the blood.  
Measuring the electrical bioimpedance of the segment is a  
15 convenient means for non-invasively determining the blood  
perfusion of the various tissues in the segment. By  
measuring the magnitude of the unchanging components of the  
bioimpedance as well as the rate and amplitude of changes  
in the bioimpedance caused by blood flow generated by the  
20 pumping action of the heart, several important cardiac  
parameters can be calculated and used to determine the  
condition of the heart.

When measuring the electrical bioimpedance of a body  
segment, such as the thorax, the primary interest is in  
25 changes in the electrical bioimpedance caused by the  
periodic increases and decreases in the quantity of blood  
in the segment caused by the periodic pumping action of the  
heart. The thoracic area of the human body is typically  
the principal area where measurements of the cardiovascular  
30 bioimpedance occur because of the presence of large blood  
vessels that have significant changes in blood quantity  
throughout the cardiac cycle. However, changes in the  
thorax during respiration also cause changes in the  
electrical bioimpedance of the thorax and thus cause major  
35 difficulties in measuring the electrical bioimpedance of

-2-

the cardiovascular activity in the thoracic area. The changes in the bioimpedance due to respiration are approximately an order of magnitude greater than the changes in electrical bioimpedance caused by the heart and are superimposed over the smaller cardiovascular bioimpedance changes to form a composite bioimpedance signal.

Some devices presently being used require voluntary apnea to take a measurement of the cardiovascular component of bioimpedance. However, this requirement of apnea makes it extremely difficult, if not impossible, to measure the cardiovascular bioimpedance in many instances. Often voluntary apnea cannot be performed because the person whose bioimpedance is being measured is unconscious, under anesthesia, or ill. Further, even when voluntary apnea may be performed the undisturbed cardiovascular electrical bioimpedance can be measured only for a short time.

Moreover, it is difficult, if not impossible, to completely separate the cardiovascular bioimpedance signals from the respiratory bioimpedance signals by using filtering. A common approach has been to use the first derivative of the composite of the bioimpedance signal. This reduces the magnitude of the problem because the derivative reduces the lower frequency/higher magnitude respiratory part of the bioimpedance signal. One such method, disclosed in U.S. Patent No. 4,450,527, calculates and uses a sliding average of the maximum rate of impedance change over four heart beats to further offset the effects of respiratory bioimpedance. Even with the improved methods presently available, respiratory changes in the bioimpedance continue to interfere with the accurate measurement of cardiovascular bioimpedance.

#### Summary of the Invention

The present invention includes an apparatus for non-invasively measuring the cardiac output of a patient

-3-

through the use of a bioimpedance measuring device while advantageously suppressing or eliminating the unwanted effects of respiration. A typical bioimpedance measuring device comprises a high frequency, constant amplitude

5 current source, the output of which is injected through a portion of the patient's body between a pair of current injecting electrodes. A pair of sensing electrodes senses the voltage across a second (inner) portion of the

10 portion of the patient's body. The outputs of the voltage sensing electrodes are connected to an amplifier that provides an amplified electrical bioimpedance signal at its output. The electrical bioimpedance signal corresponds to the patient's thoracic impedance as a function of time.

15 The bioimpedance measuring device further employs a differentiating circuit that differentiates the electrical bioimpedance signal in order to generate a differentiated electrical signal corresponding to the rate of change of thoracic impedance as a function of time. The apparatus of

20 the present invention is characterized by a clamping circuit that periodically clamps the differentiated electrical signal so that the signal is active only for a predetermined time following the beginning of each cardiac cycle. The circuit advantageously suppresses or eliminates

25 the unwanted effects of respiration on bioimpedance measurements by forcing the signal to begin from a baseline voltage at the beginning of each cardiac cycle.

In a preferred embodiment of the apparatus of the present invention, the clamping circuit comprises an

30 electronic switch that is timed to be closed except during a predetermined time following the beginning of each cardiac cycle. The preferred embodiment of the clamping circuit also employs a coupling capacitor that is placed between the input of the clamping circuit and the source of

35 the signal to be clamped. The invention further includes a

-4-

clamping control circuit that is responsive to the patient's electro-cardiac signals so that the clamping control circuit is synchronized with the patient's cardiac cycle. ~~The clamping control circuit provides an output~~

5: signal that controls the closing of the electronic switch that comprises the clamping circuit. When the electronic switch is closed, the signal is clamped to a baseline voltage. When the switch is opened, the opposing voltage stored across the coupling capacitor forces the signal to  
10: start from that same baseline voltage. The effects of respiration on the electrical bioimpedance signal are thereby suppressed or eliminated since the respiratory contribution is typically of greater magnitude and lower frequency than the cardiac contribution.

15: In accordance with a preferred embodiment of the invention, the clamping circuit is located at the input of the differentiating circuit of the bioimpedance measuring device. In an alternative embodiment the clamping circuit and the coupling capacitor are placed at the output of the  
20: differentiating circuit. In either embodiment, the differentiated bioimpedance signal is clamped by the operation of the clamping circuit.

According to another aspect of the present invention, there is also disclosed a method of measuring the cardiac  
25: output of the heart of a patient comprising the steps of applying a high frequency constant current to a first portion of the patient's body, sensing a voltage developed across a second portion of the patient's body caused by the flow of the high frequency constant current through the  
30: first portion, amplifying the sensed voltage and differentiating the sensed voltage to provide a differentiated output signal. The method of the present invention is characterized by the step of clamping the differentiated output signal so that the differentiated  
35: output signal has a fixed magnitude during a selected time period prior to the mechanical systole of the patient's

-5-

heart and has a variable magnitude corresponding to the rate of change of the sensed voltage during the mechanical systole of the heart.

Brief Description of the Drawings

5        Figure 1 is a block diagram illustrating the components of a typical bioimpedance measuring device.

Figure 2A is a graph of a typical electrical bioimpedance signal  $Z(t)$  caused by cardiac activity where the patient is participating in voluntary apnea.

10       Figure 2B is a graph of a differentiated electrical signal  $dZ/dt$  which is the derivative of the electrical bioimpedance signal  $Z(t)$  shown in Figure 2A.

Figure 2C is a graph of a typical electrical bioimpedance signal  $Z(t)$  modulated by the electrical  
15 bioimpedance signal caused by respiration (shown in dashed lines).

-6-

Figure 2D is a differentiated electrical signal  $dZ/dt$  which is the derivative of the electrical bioimpedance signal  $Z(t)$  shown in Figure 2C.

Figure 3A is a block diagram that illustrates a preferred embodiment of the clamping portion of the present invention.

Figure 3B is a block diagram that illustrates an alternative embodiment of the clamping portion of the present invention.

Figure 4 is an illustration of the timing relationship that exists between a typical electrocardiogram signal, a typical electrical bioimpedance signal  $Z(t)$ , and a typical differentiated electrical signal  $dZ/dt$ .

Figure 5A is a graph of a typical electrical bioimpedance signal  $Z(t)$  modulated by the electrical bioimpedance signal caused by respiration (shown in dashed lines), also shown in Figure 2C.

Figure 5B is a graph of the signal shown in Figure 5A as it would appear when clamping is of minimum duration.

Figure 5C is a graph of the signal shown in Figure 5A as it would appear when clamping is of maximum duration.

Figure 6A is a graph of the differentiated electrical signal  $dZ/dt$ , also shown in Figure 2D, which is the derivative of the electrical bioimpedance signal  $Z(t)$  shown in Figures 2C and 5A.

Figure 6B is a graph of the signal shown in Figure 5A as it would appear when clamping is of minimum duration.

Figure 6C is a graph of the signal shown in Figure 5A as it would appear when clamping is of maximum duration.

Figure 7 is a block diagram illustrating a preferred embodiment of the invention.

Figure 8 is a detailed circuit diagram of a preferred embodiment of the electrical circuitry of the invention.



-7-

Detailed Description of the Preferred Embodiment

Figure 1 diagrammatically illustrates a typical apparatus for measuring the cardiac output of a patient 100. In order to obtain thoracic cardiovascular data, the output of a high frequency constant current source 102 is applied to a segment of the body of the patient 100 through a pair of current injecting electrodes 104 and 106, shown in Figure 1 as a pair of spot electrodes. For example, in Figure 1, the segment of the patient's body is the thorax. A voltage is generated across the body segment by the flow of the high frequency current through the tissues between the two current injecting electrodes 104 and 106. The voltage is proportional to the magnitude of the constant current and also proportional to the electrical bioimpedance of the tissues between the two current injecting electrodes 104 and 106. The voltage is detected by a pair of voltage sensing electrodes 110 and 112 located on the body segment between the two current injecting electrodes 104 and 106. It should be understood that in many applications, the injection of current and the sensing of voltage may be accomplished with an array of electrodes rather than with two pairs of electrodes as shown herein for simplicity. The appropriate placement of the electrode array, represented herein by the electrodes 104, 106, 110 and 112, is disclosed by U.S. Patent No. 4,450,527, which is incorporated herein by reference.

The two sensing electrodes 110 and 112 are electrically connected to the input of a differential amplifier 114. The voltage detected by the sensing electrodes 110 and 112 is amplified by the differential amplifier 114 to produce an electrical bioimpedance signal  $Z(t)$  directly related to the bioimpedance of the patient's thorax as a function of time. This electrical bioimpedance signal  $Z(t)$  is then provided as an input to a differentiating circuit 116 that differentiates the  $Z(t)$  signal and produces a

-8-

differentiated electrical signal  $dZ/dt$  that corresponds to the rate of change of thoracic impedance as a function of time. The electrical bioimpedance signal  $Z(t)$  and the differentiated electrical signal  $dZ/dt$  are provided as

5 inputs to a signal processing circuit 120 that analyzes one or both of the signals and calculates cardiac parameters that correspond to changes in the electrical bioimpedance signal. The calculated parameters are communicated to an operator by a visual display 122 such as a video monitor, a

10 printer, or the like.

The operation of the exemplary bioimpedance measuring system of Figure 1 can be understood by referring to Figures 2A and 2B which illustrate waveforms of exemplary electrical bioimpedance signals. Figure 2A shows a typical

15 voltage waveform generated by the differential amplifier 114 in Figure 1 caused by cardiovascular activity where the patient is participating in voluntary apnea. Since the current applied to the body segment of the patient 100 in Figure 1 is constant, the changes in the amplitude of the

20 voltage generated by the differential amplifier correspond to changes in the electrical bioimpedance of the body segment caused by changes in the volume of blood in the segment throughout the cardiac cycle and is thus labelled as  $Z(t)$  in Figure 2A. It should be understood that the

25 waveform in Figure 2A does not include the high frequency components of the detected voltage as such components are filtered out by the use of a conventional low-pass filter (not shown).

It should be understood that the increase in blood flow

30 during the mechanical systole of the heart causes a decrease in the electrical bioimpedance of the thoracic area of the body. However, the differential amplifier 114 typically inverts the  $Z(t)$  signal so that the  $Z(t)$  signal is typically illustrated as shown in Figure 2A with a

35 positive-going transition corresponding to increased blood

-9-

perfusion during mechanical systole. This convention is used on the illustrations of the electrical bioimpedance  $Z(t)$  throughout this specification.

Figure 2B illustrates a voltage waveform corresponding to the differentiated electrical signal  $dZ/dt$  generated by the differentiator 116 of Figure 1 and is thus the derivative of the electrical bioimpedance signal shown in Figure 2A.

As set forth above, the signal waveforms illustrated in Figures 2A and 2B are idealized waveforms that assume that the patient is holding his or her breath (i.e., apnea). The ideal signals illustrated by Figures 2A and 2B are often not available since voluntary apnea is difficult, if not impossible, to accomplish by a patient who is ill or under anesthesia. The signal more commonly available at the output of the differential amplifier 114 is illustrated by Figure 2C which illustrates the electrical bioimpedance signal  $Z(t)$  due to cardiac activity modulated by the electrical bioimpedance signal caused by respiratory activity (shown in dashed lines). It is desirable that changes in the electrical bioimpedance signal caused by the cardiovascular activity be isolated from those changes caused by respiration. Since the harmonic content of the that portion of the bioimpedance signal caused by respiration is relatively low in comparison to that portion of the bioimpedance signal caused by the systolic portion of the cardiac activity, it has been found that the signal-to-noise ratio of the cardiac-induced changes in electrical bioimpedance can be improved by differentiating the electrical bioimpedance signal  $Z(t)$  shown in Figure 2C to obtain the differentiated electrical signal  $dZ/dt$  shown in Figure 2D. However, it can be seen that the  $dZ/dt$  signal waveform in Figure 2D comprises considerable variations in its amplitude caused by the changes in electrical bioimpedance caused by respiration.

-10-

While using the differentiated electrical signal reduces the magnitude of the respiration-induced problem, the problem still remains, particularly with respect to the determination of the maximum rate of impedance change as indicated by the maxima of the  $dZ/dt$  signal. Because the relative first harmonic frequencies of normal breathing and the heart are in approximately a 1 to 4 ratio, one method previously used to suppress the effects of respiration involved the calculation of a sliding average of the maximum rate of impedance change (the  $dZ/dt$  maxima) over four heartbeats. Such a method is disclosed in U.S. Patent No. 4,450,527.

In addition to generating substantial unwanted excursions in the  $Z(t)$  and  $dZ/dt$  signals, as discussed above, the respiration-induced changes in the electrical bioimpedance signals tend to be large compared to the cardiac-induced changes in the electrical bioimpedance signals. As a result, the circuits used to differentiate and amplify the composite electrical bioimpedance signals are caused to operate over a larger range of input magnitudes than if the cardiac-induced electrical bioimpedance signal alone were differentiated and amplified.

The present invention provides a novel apparatus and method for substantially reducing or eliminating the effects of respiration in bioimpedance measurements by obtaining all the desired information during a time interval in each cardiac cycle corresponding to the mechanical systole of the heart. An important aspect of the present invention is the use of the electrocardiogram (ECG) signal to time the operation of a signal clamping circuit to be described below.

Figure 4 illustrates the timing relationship between an electrocardiogram (ECG) signal of the patient's heartbeat, the electrical bioimpedance signal  $Z(t)$ , and the

-11-

differentiated signal  $dZ/dt$ . Figure 4 further illustrates the relationship between the above signals and the Pre-Ejection Period (the PEP interval), the mechanical systole, and the mechanical diastole of the heart. Referring to Figure 4, it can be seen that the commencement of the mechanical systole can be predicted by the occurrence of the QRS wave of the patient's electrocardiogram. The period of time between the onset of Q of the QRS complex and the commencement of the mechanical systole is referred to as the Pre-Ejection Period (PEP) of the heart and is typically greater than 40 ms. It can also be seen that the changes in electrical bioimpedance  $Z(t)$  and the corresponding changes in the differentiated electrical bioimpedance signal  $dZ/dt$  caused by the increased flow of blood during mechanical systole do not occur until after the conclusion of the Pre-Ejection Period. Since the primary indication of the heart's ability to pump blood through the vascular system of the patient's body is the heart's ability to rapidly increase the quantity of blood in the descending aorta during mechanical systole, it is generally sufficient to analyze the electrical bioimpedance signal  $Z(t)$  and/or the differentiated electrical bioimpedance signal  $dZ/dt$  during the time corresponding to the mechanical systole of the heart. During the rest of the heart cycle, it is not necessary to analyze the fluctuations in the  $Z(t)$  and the  $dZ/dt$  signals. Thus, it has been found that these fluctuations in the signals can be suppressed without losing significant electrical bioimpedance information related to the cardiac output.

As will be described below, the present invention includes a clamping circuit having an electronic switch that is controlled by the QRS wave of the ECG signal of the patient's heart. The electrical bioimpedance signal  $Z(t)$  or the differentiated electrical bioimpedance signal  $dZ/dt$  is clamped in synchronization with the ECG signal so that

-12-

the fluctuations in the clamped signal are suppressed prior to the beginning of the mechanical systole of the heart. Since it is only important that the signal be clamped prior to the beginning of the mechanical systole of the heart, the clamping of the  $Z(t)$  signal or the  $dZ/dt$  signal can begin as early as the end of the previous mechanical systole or begin as late as the occurrence of the preceding ECG Q-wave. Hence, the clamping has a minimum time duration approximately equal to the minimum PEP interval and has a maximum time duration approximately equal to the duration of the mechanical diastole.

The general concept of the present invention is illustrated in Figures 3A and 3B. In Figure 3A, the output of the differential amplifier 114 is capacitively coupled to the input of the differentiator 116 by a capacitor 140. The capacitor 140 couples the AC components of the signal output of the differential amplifier 114 to the input of the differentiator 116 and blocks the DC components of the signal. An electrically-controlled switch 142 is electrically connected between the input of the differentiator 116 and a baseline voltage reference 144. Although shown as a simple mechanical switch, it should be understood that the electrically-controlled switch 142 is an electronic switch that opens and closes in response to an electrical input signal. One embodiment of such a switch will be disclosed in more detail below.

When the electrically-controlled switch is open, the signal output of the differential amplifier 114 is coupled to the input of the differentiator 116. When the electrically-controlled switch is closed, the input of the differentiator is clamped to the voltage of the baseline voltage reference 144. The difference in the baseline voltage and the output voltage of the differential amplifier 114 appears as a voltage across the coupling capacitor 140. In Figure 3A, the output of the

-13-

differentiator 116 is the differentiated bioimpedance signal  $dZ/dt$ , and is provided as the input to the signal processing circuitry 120 (Figure 1) or other circuitry, such as will be described below.

5 The operation of the circuit in Figure 3A is illustrated by the voltage waveforms in Figures 5A, 5B and 5C. The voltage waveform in Figure 5A generally corresponds to the voltage waveform in Figure 2C and represents the  $Z(t)$  output of the differential amplifier 114. As illustrated, 10 the voltage waveform in Figure 5A includes relatively large fluctuations caused by the combined effects of respiration combined with relatively small fluctuations caused by changes in blood flow during the cardiac cycle.

Figure 5B illustrates the voltage waveform on the input 15 of the differentiator 116 and demonstrates the effect of the electrically-controlled switch 142 on that voltage waveform when the electrically-controlled switch is closed for a short amount of time prior to the beginning of the mechanical systole of the heart. As illustrated in Figure 20 5B, when the electrically controlled switch 142 is open, as during a time interval A, the voltage on the input of the differentiator 116 follows the voltage on the output of the differential amplifier 114. On the other hand, when the electrically-controlled switch 142 is closed, as during a 25 time interval B, the voltage on the input of the differentiator 116 is clamped to the baseline voltage as shown. In Figure 5B, the time interval B generally corresponds to the time from the occurrence of the QRS wave of the ECG signal to the beginning of mechanical systole. 30 Thus, when the electrically-controlled switch 142 is again opened at the beginning of a time interval C, corresponding to the beginning of the mechanical systole of the heart, the voltage on the input of the differentiator 116 will begin changing from the baseline voltage and will be 35 responsive to the fluctuations caused by the blood flow

-14-

generated during the mechanical diastole of the heart. Thereafter, the voltage on the input of the differentiator 116 will change in accordance with the changes in the output voltage from the differential amplifier 114 until

5 the electrically-operated switch is again closed during a time interval D. Thus, rather than the voltage on the input of the differentiator 116 following the extreme voltage swings of the output of the differential amplifier 114, it has relatively small voltage swings that begin at  
10 the baseline voltage and only change as much as the output voltage of the differential amplifier changes in one cardiac cycle. Time interval E again corresponds to a time when the electrically-controlled switch is open and time interval F corresponds to a time when the electrically-  
15 controlled switch is closed.

Figure 5C illustrates a voltage waveform on the input of the differentiator 116 when the electrically-controlled switch 142 is closed throughout substantially all of the mechanical diastole portion of the cardiac cycle. Thus,  
20 the voltage on the input of the differentiator 116 is clamped to the baseline voltage at all times other than the mechanical systole portion of the heart cycle. This has the advantage of further suppressing the voltage swings applied to the input of the differentiator 116. In Figure  
25 5C, the time intervals A, C and E correspond to times when the electrically-controlled switch 142 is open and the time intervals B, D and F correspond to times when the electrically-controlled switch 142 is closed.

Figure 3B illustrates an alternative circuit to the circuit in Figure 3A. In Figure 3B, the output of the  
30 differential amplifier 114 is connected directly to the input of the differentiator 116. On the other hand, the output of the differentiator 116 is not provided directly as an output. Rather, the output of the differentiator 116  
35 is coupled through a coupling capacitor 146 to provide an



-15-

AC-coupled output signal  $dZ/dt_{OUT}$ . In the embodiment of Figure 3B, the AC-coupled output signal  $dZ/dt_{OUT}$  is electrically connected to the electrically-controlled switch 144 that is connected to the baseline reference voltage 144, as before. In Figure 3B, when the electrically-controlled switch 144 is open, the output of the differentiator 116 is coupled through the coupling capacitor 146 so that the AC-coupled output signal  $dZ/dt_{OUT}$  tracks the output of the differentiator 116. When the electrically-controlled switch 144 is closed, the AC-coupled output signal  $dZ/dt_{OUT}$  is clamped to the baseline reference voltage so that any changes in the voltage generated by the differentiator 116 appear across the coupling capacitor 146.

The operation of the embodiment of Figure 3B is illustrated in Figures 6A, 6B and 6C. Figure 6A shows a typical differentiated electrical bioimpedance signal  $dZ/dt$ , for example, such as that provided as an output of the differentiator 116. As set forth above, the fluctuations of the differentiated electrical signal  $dZ/dt$  are reduced compared to the fluctuations of the electrical bioimpedance signal  $Z(t)$ ; however, the  $dZ/dt$  signal has large low frequency voltage swings that are not completely suppressed by the differentiation. Figure 6B shows the  $dZ/dt_{OUT}$  signal after having passed through the coupling capacitor 146 and when being selectively clamped by the electrically-controlled switch 142. In Figure 6B, the electrically-controlled switch 142 in the embodiment of Figure 3B is closed from time of occurrence of the QRS portion of the ECG signal to the beginning of the mechanical systole of the cardiac cycle. Thus, the amplitude of the voltage of the  $dZ/dt_{OUT}$  signal in Figure 6B begins at the baseline reference voltage at the beginning of each mechanical systole. Time intervals A, C and E correspond to times when the electrically-controlled

-16-

switch is open, and time intervals B, D and F correspond to times when the electrically-controlled switch is closed.

Figure 6C illustrates the  $dZ/dt_{OUT}$  signal when the electrically-controlled switch 142 is closed to clamp the  $dZ/dt_{OUT}$  signal from the end of mechanical systole to the beginning of the next mechanical systole (i.e., throughout substantially all of the mechanical diastole). Clamping throughout mechanical diastole substantially reduces the voltage fluctuations in the  $dZ/dt_{OUT}$  signal.

As set forth above, the present invention provides a novel apparatus and method for reducing or eliminating the effects of respiration in bioimpedance measurements by taking advantage of the fact that all of the desired information can be obtained during a reoccurring period of known duration. More specifically all of the desired data can be quantified during the mechanical systole of the heart. The undesirable effects of respiration are greatly reduced by clamping the bioimpedance signal or the differentiated bioimpedance signal to a baseline voltage level and holding it at the baseline voltage until just before commencement of the mechanical systole. The clamping provided by the present invention has the desirous effect of causing the electrical bioimpedance signal (Figures 5B and 5C) or the differentiated electrical bioimpedance signal (Figures 6B and 6C) to begin from a fixed base level at the beginning of each mechanical systole, thus reducing the extremes in the voltage changes in the electrical bioimpedance signal caused by respiration that occur randomly in relation to the cardiac cycle.

The operation of the present invention when incorporated into an electrical bioimpedance system is further illustrated in block diagram form in Figure 7. As explained above in relation to Figure 1, a high frequency current source 102 is employed to create a voltage across the patient's thorax between sensing electrodes 110 and 112

-17-

by injecting current with the injecting electrodes 104 and 106. The voltage generated between the sensing electrodes 110 and 112 is detected by the differential amplifier 114 and further amplified by an inverting amplifier 150. The amplified electrical bioimpedance signal  $Z(t)$  is then coupled through the coupling capacitor 140 and through the clamping circuit 142 (i.e., the electrically-controlled switch 142) to the input of the differentiator 116.

The clamping circuit 142 is controlled by a clamping control circuit 154 that is synchronized by a -ECG signal generated by an ECG amplifier 156. The ECG amplifier 156 is electrically connected to the sensing electrodes 110, 112 and operates in a conventional manner to generate an amplified electrical signal having a negative maximum corresponding to the R-wave of the QRS complex of cardiac electrical activity. The R-wave causes the triggering of the clamping control circuit 154, as will be discussed below.

The output of the differentiator 116 is provided as an input to a variable gain amplifier 160. The variable gain amplifier 160 is adjusted so that 1 volt = 1 ohm/second. In other words, a one-volt signal output from the variable gain amplifier 160 corresponds to a one-ohm per second rate of change in the electrical bioimpedance ( $dZ/dt = 1$  ohm/second). The variable gain amplifier 160 amplifies the differentiated electrical signal and outputs the amplified signal to a low pass filter 162. The low pass filter 162 has a cutoff frequency of approximately 30 Hz and removes 60 Hz noise associated with the supply line voltage along with other high frequency noise. The differentiated electrical signal  $dZ/dt$  is provided to the input of the processing circuit 120 so that the desired cardiac parameters can be determined and communicated to the operator by the visual display 122, or otherwise. Since the electrical bioimpedance signal  $Z(t)$  is clamped prior to

-18-

the input of the differentiator 116, the signal provided as an input to the signal processing circuit 120 will not have the large voltage fluctuations that it would have if the clamping circuit were not present. In Figure 7, the coupling capacitor 140 and the clamping circuit 142 are connected between the inverting amplifier 150 and the differentiator 116, corresponding to the embodiment of Figure 3A. It should be understood that in an alternative embodiment (not shown) to the embodiment of Figure 7, the coupling capacitor 140 and the clamping circuit 142 are interposed between the output of the differentiator 116 and the input of the variable gain amplifier 160, in accordance with Figure 3B.

Figure 8 is a detailed circuit diagram showing a preferred embodiment of the inverting amplifier 150, the coupling capacitor 140, the clamping circuit 142 (i.e., the electrically-controlled switch 142), the clamping control circuit 154, the differentiator 116, the variable gain amplifier 160, and the low pass filter 162. The inverting amplifier 150 is designed so as to have a selected gain A (e.g.,  $A = -100$ ). The electrical bioimpedance signal  $Z(t)$  output by the differential amplifier 114 (Figure 6) is received by the inverting amplifier 150 and amplified in order to increase the amplitude of the signal to a usable value. The amplified electrical bioimpedance signal  $AZ(t)$  output by the inverting amplifier 150 is provided as an input to the clamping circuit 142 through the coupling capacitor 140. The clamping circuit 142 is controlled by the clamping control circuit 154 which, in the preferred embodiment, is advantageously a standard 555 timer connected for monostable operation. In the embodiment shown, the passive timing elements are selected so as to cause the 555 timer to have a triggered pulse duration of approximately 40 ms, approximately equal to the minimum duration of the PEP interval. The trigger for the clamping

-19-

control circuit 154 is derived in a conventional manner from the R-wave of the QRS complex of the electrocardiogram of the patient's heart so that the pulse output of the clamping control circuit is active for approximately 40 ms after the beginning of the QRS wave. The electrical bioimpedance signal  $Z(t)$  is clamped during the 40 ms pulse duration of the clamping control circuit 154. Thus, in the embodiment shown, the clamping circuit 142 is active during most of the PEP interval and is released just prior to the beginning of the mechanical systole of the patient's heart. The clamping action corresponds to the clamping action described above in connection with Figure 5B. The clamped and amplified electrical bioimpedance signal is then provided as an input to differentiator 116 which differentiates the clamped  $Z(t)$  signal and provides a differentiated output signal  $dZ/dt$ . The differentiated electrical signal  $dZ/dt$  is provided as an input to the variable gain amplifier 160. The variable gain amplifier 160 is adjusted such that each 1 ohm/second variation in the rate of change of the electrical bioimpedance signal  $Z(t)$  corresponds to a 1 volt variation at the output of the variable gain amplifier 160. The signal output of the variable gain amplifier 160 is then passed through the low pass filter 162 in order to remove any high frequency noise.

As set forth above, the electrically-controlled switch or clamping circuit 142 is an electronic switch that is controlled by the output of the 555 timer in the clamping control circuit 154. It should be understood that the voltage output of the inverting amplifier has both positive and negative voltage swings with respect to a circuit ground reference. Thus, the clamping circuit 142 must be able to clamp either polarity of voltage swing to the baseline voltage reference. A detailed description of the operation of an exemplary preferred embodiment of the

-20-

clamping circuit 142 shown in Figure 8. This particular embodiment advantageously clamps both the positive and negative output of the inverting amplifier 150. The amplified electrical bioimpedance signal  $AZ(t)$  generated by the inverting amplifier 150 is capacitively coupled to the clamping circuit 142 through the capacitor 140. While the output of the 555 timer in the clamping control circuit 154 is low (approximately 0.1 to 0.25 volts), no clamping occurs since transistor 164 is in cutoff and negligible current flows from the collector to the emitter of transistor 164. Furthermore, the diode 170 is reverse biased to prevent the diode 170 and the resistor 172 from effecting the amplified electrical bioimpedance signal.

When the ECG trigger causes the output of the clamping control circuit 154 to go high, its output will be approximately 4 volts. The voltage available at the base-emitter junction, after the voltage drop across the biasing resistor 166 and the capacitor 168, will cause the transistor 164 to saturate. The collector-emitter saturation voltage,  $V_{ce(sat)}$ , of the transistor 164 will be approximately equal to 0.2 volts and the voltage drop across the now forward biased diode 174 will be approximately 0.7 volts. Hence, during clamping, the voltage at the output of the clamping circuit 142 equals the sum of the voltages across the diode 174 and the collector-emitter junction of the transistor 164 and will be approximately 0.9 volts. Whenever the clamping circuit 142 is active, the diode 170 and the resistor 172 are operating as a relatively constant 7.9 mA current source to both the diode/transistor 174, 164 combination and the coupling capacitor 140 in order to maintain a constant 0.9 volts at the output of the clamping circuit 142. The current provided by the diode 170 and the resistor 172 is equal to the current through the resistor 172 which can be calculated using the following equation:

-21-

$$\frac{V_{555 \text{ Timer}} - V_{\text{Diode}} - 0.9v}{R_{172}}$$

$$R_{172}$$

5 where  $V_{555 \text{ Timer}}$  is the high level output voltage of the  
 555 timer (e.g., approximately 4.0 volts),  $V_{\text{Diode}}$  is the  
 forward voltage drop of the diode 170 (e.g., approximately  
 0.7 volts) and  $R_{172}$  is the resistance of the resistor 172  
 (e.g., 330 ohms). When the appropriate values are  
 10 substituted for the above variables, the following is  
 obtained:

$$\frac{4.0v - 0.7v - 0.9v}{330 \text{ Ohms}} = \frac{2.6v}{330 \text{ Ohms}} = 7.9 \text{ mA}$$

15

The output of the inverting amplifier 150 supplies the  
 charging current to the coupling capacitor 140 when the  
 amplified electrical bioimpedance signal  $AZ(t)$  is greater  
 20 than 0.9 volts. In the event that the amplified electrical  
 bioimpedance signal  $AZ(t)$  drops below 0.9 volts, the  
 forward biased diode 170 and the resistor 172 will source  
 the charging current required by the coupling capacitor  
 140. Hence, it can be seen from Figure 8 and the  
 25 description of the clamping circuit 142 herein, when the  
 output of the clamping control circuit is high, the output  
 of the clamping circuit will be a steady base-line voltage  
 of approximately 0.9 volts.

By clamping one side of the coupling capacitor 140 to a  
 30 baseline voltage of approximately 0.9 volts, any change in  
 the electrical bioimpedance signal above or below that  
 baseline voltage is stored across coupling capacitor 140.  
 In other words, the amplitude of the electrical  
 bioimpedance signal at the beginning of the mechanical  
 35 systole, less the baseline voltage of approximately 0.9  
 volts, is caused to be stored across coupling capacitor 140

-22-

in opposite polarity in relation to the incoming electrical bioimpedance signal. When the clamping circuit 142 is released, the electrical bioimpedance signal is re-coupled to the differentiator 116 through coupling capacitor 140.

5 Any variation in the electrical bioimpedance signal above or below the base-line voltage of 0.9 volts that is present just prior to release of the clamping circuit 142 is negated by that voltage variation having been stored across the coupling capacitor 140 when the clamping circuit 142  
10 was active. The net result is that any changes in the electrical bioimpedance signal caused by respiration are suppressed except during the short period of time during which cardiac data is being quantified. Although the respiratory contribution is not suppressed during this  
15 short period of quantification, it is approximately a linear function and therefore can be removed by simple algorithmic means. Clamping the electrical bioimpedance signal to approximately 0.9 volts until just before the mechanical systole has the additional advantageous effect  
20 of preventing the respiratory signal, roughly an order of magnitude larger than the electrical bioimpedance signal due to cardiac activity, from driving the electronic circuitry (e.g. the differentiator 116 and the variable gain amplifier 160) out of its linear range.

25 In the embodiment illustrated in Figure 8, the differentiator 116 includes a differentiating capacitor 180, a differentiating resistor 182, a first bias resistor 184, a second bias resistor 186 and a filter capacitor 188. The first bias resistor 184 and the second bias resistor  
30 186 are connected in series between a DC power source (e.g., +5 volts) and a ground reference to provide a voltage divider network having a reference voltage (e.g., 1.56 volts) at a reference node 190 corresponding to the common connection between the two resistors 184, 186. The  
35 filter capacitor 188 is connected between the reference



-23-

node 190 and the ground reference to substantially reduce or eliminate any noise at the reference node 190. The differentiating capacitor 180 has a first terminal connected to the output of the clamping circuit 142 and has  
5 a second terminal connected to the input of the variable gain amplifier 160. The differentiating resistor 182 has a first lead connected to the second terminal of the differentiating capacitor 180 and has a second lead connected to the reference node 190. The differentiating  
10 capacitor 180 and differentiating resistor 182 operate in a conventional manner to differentiate the signal output of the clamping circuit 142 and provide the differentiated output as the input to the variable gain amplifier 160. However, since the second lead of the differentiating  
15 resistor 182 is connected to the reference node 190 rather than the ground reference, the differentiated output signal is biased to a positive voltage with respect to ground so that for small voltage swings when the electrical bioimpedance signal is unclamped during mechanical systole  
20 the voltage applied to the input of the variable gain amplifier 160 is positive.

While the description focused on the clamping operation occurring before the differentiator 116, it should be appreciated that clamping can be implemented after the  
25 differentiator 116 as shown in Figure 3B. Clamping the  $dZ/dt$  signal generated by the differentiator 116 has the same effect of reducing the voltage swing of the differentiated signal so that the electrical circuit operates within a limited voltage range during the  
30 mechanical systole of the heart.

As set forth above, the clamping circuit is operated so that the electrical bioimpedance signal is forced to the baseline voltage immediately prior to the beginning of the mechanical systole of the heart. Thus, although the  
35 electrical circuits may have been operating outside their

-24-

linear ranges prior to the occurrence of the QRS wave, the operation of the clamping circuit brings all of the electrical signals following the clamping circuit within the linear range of the circuits prior to the beginning of the mechanical systole.

5 In an alternative embodiment not shown, the timing of the clamping control circuit 154 can be adjusted to maintain the differentiated electrical bioimpedance signal in the clamped condition except during a small window of  
10 time that begins before the mechanical systole and ends after the conclusion of mechanical systole. For example, two timing signals can be incorporated into the clamping control circuit. The first timing signal can be initiated by the occurrence of the QRS signal as set forth above and  
15 will have time duration substantially equal to the Pre-Ejection Period. At the conclusion of the first timing signal, a second timing signal is generated that opens the above-described clamping switch 142 for an amount of time substantially equal to the time duration of the mechanical  
20 systole of the heart. When the second timing signal concludes, the clamping switch 142 then closes until the beginning of the next mechanical systole. As set forth above, this embodiment has the advantage of suppressing the voltage swings except during the time when the bioimpedance  
25 signals are to be analyzed.

-25-

CLAIMS:

1. A non-invasive apparatus for measuring the cardiac output of a patient, comprising:

5 a bioimpedance measuring device (102, 104, 106, 110, 112, 114) that produces an electrical bioimpedance signal indicative of the thoracic impedance as a function of time;

10 a differentiating circuit (116) that receives a signal responsive to said electrical bioimpedance signal, and that differentiates said signal responsive to said electrical bioimpedance signal so as to generate a differentiated electrical signal indicative of the rate of change of thoracic impedance as a function of time, characterized by

15 a clamping circuit (142) that periodically clamps said differentiated electrical signal so that said differentiated electrical signal is active only for a predetermined time duration following the beginning of each cardiac cycle.

20 2. The apparatus as defined in Claim 1, further characterized in that said bioimpedance measuring device comprises:

a current source (102) having a high frequency constant amplitude electrical current output;

25 a pair of injector electrodes (104, 106) that inject the current output into a first portion of a patient's body;

30 a pair of sensor electrodes (110, 112) that sense a voltage across a second portion of the patient's body caused by current flow in said first portion of the patient's body; and

35 an amplifier (114) connected to said pair of sensor electrodes (110, 112) that receives said voltage and generates said electrical signal indicative of the thoracic impedance as a function of time.

-26-

3. The apparatus as defined in Claim 2, further characterized in that said clamping circuit (142) comprises an electrically controlled switch, said switch being timed to be closed except during said predetermined time  
5 following the beginning of each cardiac cycle.

4. The apparatus as defined in Claim 3, further characterized by a timing circuit (154) to control said switch, said timing circuit (154) providing an output signal that controls the closing of said switch, said  
10 timing circuit (154) responsive to the ECG output signals from the heart of the patient so that the operation of said switch is synchronized with the ECG output signals from the heart of the patient.

5. The apparatus as defined in Claim 3, further  
15 characterized in that said electrically controlled switch is located at the input of said differentiating circuit (116) so that said electrically controlled switch clamps said signal responsive to said electrical bioimpedance signal.

20 6. The apparatus as defined in Claim 5, further characterized in that said electrically controlled switch clamps said signal responsive to said electrical bioimpedance signal to a predetermined baseline voltage (144).

25 7. The apparatus as defined in Claim 3, further characterized in that said electrically controlled switch is located at the output of said differentiating circuit (116).

30 8. The apparatus as defined in Claim 7, further characterized in that said electrically controlled switch clamps said output of said differentiating circuit to a predetermined baseline voltage (144).

9. A method of measuring the cardiac output of the heart of a patient comprising the steps of:  
35 applying a high frequency constant current to a first portion of the patient's body;

-27-

sensing a voltage developed across a second portion of the patient's body caused by the flow of said high frequency constant current through said first portion;



5        amplifying said sensed voltage; and

differentiating said sensed voltage to provide a differentiated output signal, characterized by the step of

10        clamping said differentiated output signal so that said differentiated output signal has a fixed magnitude during a selected time period prior to the mechanical systole of the patient's heart and has a variable magnitude corresponding to the rate of change of said sensed voltage during the mechanical systole  
15        of the heart.

---

1/6



SUBSTITUTE SHEET



3/6

Fig. 5A




Fig. 5B








Fig. 5C



SUBSTITUTE SHEET



4/6



SUBSTITUTE SHEET

5/6




Fig. 7

5/6

6/6




Fig. 8

# INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US88/02833

## I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) \*

According to International Patent Classification (IPC) or to both National Classification and IPC

IPC(4): A61B 5/02; G06F 15/42

U.S. CL.: 364/413.05; 128/671, 693, 734

## II. FIELDS SEARCHED

Minimum Documentation Searched <sup>7</sup>

Classification System

Classification Symbols

U.S.

364/413.05; 128/671, 693, 708, 709, 723, 734

Documentation Searched other than Minimum Documentation  
to the Extent that such Documents are Included in the Fields Searched <sup>8</sup>

## III. DOCUMENTS CONSIDERED TO BE RELEVANT <sup>9</sup>

| Category <sup>10</sup> | Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>            | Relevant to Claim No. <sup>13</sup> |
|------------------------|---|-------------------------------------|
| Y                      | US, A, 4,450,527 (SRAMEK) 22 May 1984<br>(22.05.84).  | 1-9                                 |
| Y                      | US, A, 3,994,284 (VOELKER) 30 November 1976<br>(30.11.76), see especially figure 1 and<br>column 3, lines 28-41.          | 1-9                                 |
| A                      | US, A, 4,305,400 (LOGAN) 15 December 1981<br>(15.12.81).  |                                     |
| A, P                   | US, A, 4,757,824 (CHAUMET) 19 July 1988<br>(19.07.88), see especially column 6,<br>lines 32-36 and column 8, lines 28-35. |                                     |
| A                      | US, A, 4,676,253 (NEWMAN ET AL.) 30 June 1987<br>(30.06.87).  |                                     |
| A                      | US, A, 3,976,052 (JUNGINGER ET AL.) 24<br>August 1976 (24.08.76).   |                                     |

\* Special categories of cited documents: <sup>10</sup>

"A" document defining the general state of the art which is not  
considered to be of particular relevance

"E" earlier document but published on or after the international  
filing date

"L" document which may throw doubts on priority claim(s) or  
which is cited to establish the publication date of another  
citation or other special reason (as specified)

"Q" document referring to an oral disclosure, use, exhibition or  
other means

"P" document published prior to the international filing date but  
later than the priority date claimed

"T" later document published after the international filing date  
or priority date and not in conflict with the application but  
cited to understand the principle or theory underlying the  
invention

"X" document of particular relevance: the claimed invention  
cannot be considered novel or cannot be considered to  
involve an inventive step

"Y" document of particular relevance: the claimed invention  
cannot be considered to involve an inventive step when the  
document is combined with one or more other such docu-  
ments, such combination being obvious to a person skilled  
in the art

"Z" document member of the same patent family

## IV. CERTIFICATION

Date of the Actual Completion of the International Search

27 SEPTEMBER 1988

International Searching Authority

ISA/US

Date of Mailing of this International Search Report

3 NOV 1988

Signature of Authorized Officer

Clark A. Jablon  
CLARK A. JABLON

## III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

| Category * | Citation of Document, with indication, where appropriate, of the relevant passages  | Relevant to Claim No |
|------------|---|----------------------|
| A          | US, A, 4,422,458 (KRAVATH) 27 December 1983 (27.12.83).   |                      |
| A          | <del>Biotelemetry Patient Monitoring, Vol. 8, No. 4, issued 1981, Y. Miyamoto, et al. 'Automatic determination of cardiac output using an impedance plethysmography', see pages 189-203, especially page 191, lines 8-12.</del>   |                      |
| A          | Proceedings of the Vth International Conference on Electrical Bio-impedance, issued August 1981 (Tokyo) Y. Miyamoto, et al. 'Automatic determination of cardiac output by impedance plethysmography under various conditions', see pages 45-48 and especially the abstract.                     |                      |
| A          | Biomedical Engineering, Vol. 9, No. 9, issued September 1974, W.G. Kubicek, et al. 'The Minnesota impedance cardiograph - theory and applications', see pages 410-416.  |                      |
| A          | Proceedings of the Vth International Conference on Electrical Bio-impedance, issued August 1981 (Tokyo) B.B. Sramek, 'Noninvasive technique for measurement of cardiac output by means of electrical impedance', see pages 39-42.   |                      |
| A          | Medical Electronics, issued April 1982, B.B. Sramek, 'Cardiac output by electrical impedance', see pages 93-97.   |                      |
| A          | Proceedings of the VIth International Conference on Electrical Bio-impedance, 1983 (Zadar, Yugoslavia), B.B. Sramek, et al. 'Stroke volume equation with a linear base impedance model and its accuracy, as compared to thermodilution and magnetic flowmeter techniques in human and animals'. |                      |
| A          | Medical Electronics, issued April 1983, B.B. Sramek, 'Electrical Bio-impedance', see pages 95-105.  |                      |
| A          | Geddes, "Cardiovascular Devices and their Application", published 1984 by John Wiley & Sons (New York), see pages 100-107 and 122-135.  |                      |

6/6




Fig. 8

FIG. 8

# INTERNATIONAL SEARCH REPORT

International Application No. PCT/US88/02833

## I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) <sup>6</sup>

According to International Patent Classification (IPC) or to both National Classification and IPC

IPC(4): A61B 5/02; G06F 15/42

U.S. CL.: 364/413.05; 128/671, 693, 734

## II. FIELDS SEARCHED

Minimum Documentation Searched <sup>7</sup>

| Classification System | Classification Symbols                       |
|-----------------------|--|
| U.S.                  | 364/413.05; 128/671, 693, 708, 709, 723, 734 |

Documentation Searched other than Minimum Documentation  
to the extent that such Documents are included in the Fields Searched <sup>8</sup>

## III. DOCUMENTS CONSIDERED TO BE RELEVANT <sup>9</sup>

| Category <sup>10</sup> | Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>            | Relevant to Claim No. <sup>13</sup> |
|------------------------|---|-------------------------------------|
| Y                      | US, A, 4,450,527 (SRAMEK) 22 May 1984<br>(22.05.84).  | 1-9                                 |
| Y                      | US, A, 3,994,284 (VOELKER) 30 November 1976<br>(30.11.76), see especially figure 1 and<br>column 3, lines 28-41.          | 1-9                                 |
| A                      | US, A, 4,305,400 (LOGAN) 15 December 1981<br>(15.12.81).  |                                     |
| A, P                   | US, A, 4,757,824 (CHAUMET) 19 July 1988<br>(19.07.88), see especially column 6,<br>lines 32-36 and column 8, lines 28-35. |                                     |
| A                      | US, A, 4,676,253 (NEWMAN ET AL.) 30 June 1987<br>(30.06.87).  |                                     |
| A                      | US, A, 3,976,052 (JUNGINGER ET AL.) 24<br>August 1976 (24.08.76).   |                                     |

<sup>10</sup> Special categories of cited documents:

"A" document defining the general state of the art which is not  
considered to be of particular relevance

"E" earlier document but published on or after the international  
filing date

"L" document which may throw doubts on priority claim(s) or  
which is cited to establish the publication date of another  
citation or other special reason (as specified)

"Q" document referring to an oral disclosure, use, exhibition or  
other means

"P" document published prior to the international filing date but  
later than the priority date claimed

"T" later document published after the international filing date  
or priority date and not in conflict with the application but  
cited to understand the principle or theory underlying the  
invention

"X" document of particular relevance: the claimed invention  
cannot be considered novel or cannot be considered to  
involve an inventive step

"Y" document of particular relevance: the claimed invention  
cannot be considered to involve an inventive step when the  
document is combined with one or more other such docu-  
ments, such combination being obvious to a person skilled  
in the art.

"Z" document member of the same patent family

## IV. CERTIFICATION

Date of the Actual Completion of the International Search

27 SEPTEMBER 1988

International Searching Authority

ISA/US

Date of Mailing of this International Search Report

3 NOV 1988

Signature of Authorized Officer

Clark A. Jablon  
CLARK A. JABLON

| III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET) |   |                      |
|--|---|----------------------|
| Category *   | Citation of Document, with indication, where appropriate, of the relevant passages  | Relevant to Claim No |
| A  | US, A, 4,422,458 (KRAVATH) 27 December 1983 (27.12.83).   |                      |
| A  | Biotelemetry Patient Monitoring, Vol. 8, No. 4, issued 1981, Y. Miyamoto, et al. 'Automatic determination of cardiac output using an impedance plethysmography', see pages 189-203, especially page 191, lines 8-12.  |                      |
| A  | Proceedings of the Vth International Conference on Electrical Bio-impedance, issued August 1981 (Tokyo) Y. Miyamoto, et al. 'Automatic determination of cardiac output by impedance plethysmography under various conditions', see pages 45-48 and especially the abstract.                     |                      |
| A  | Biomedical Engineering, Vol. 9, No. 9, issued September 1974, W.G. Kubicek, et al. 'The Minnesota impedance cardiograph - theory and applications', see pages 410-416.  |                      |
| A  | Proceedings of the Vth International Conference on Electrical Bio-impedance, issued August 1981 (Tokyo) B.B. Sramek, 'Noninvasive technique for measurement of cardiac output by means of electrical impedance', see pages 39-42.   |                      |
| A  | Medical Electronics, issued April 1982, B.B. Sramek, 'Cardiac output by electrical impedance', see pages 93-97.   |                      |
| A  | Proceedings of the VIth International Conference on Electrical Bio-impedance, 1983 (Zadar, Yugoslavia), B.B. Sramek, et al. 'Stroke volume equation with a linear base impedance model and its accuracy, as compared to thermodilution and magnetic flowmeter techniques in human and animals'. |                      |
| A  | Medical Electronics, issued April 1983, B.B. Sramek, 'Electrical Bio-impedance', see pages 95-105.  |                      |
| A  | Geddes, "Cardiovascular Devices and their Application", published 1984 by John Wiley & Sons (New York), see pages 100-107 and 122-135.  |                      |